Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Crinetics Pharmaceuticals (CRNX) over the last 5 years, with Dec 2024 value amounting to $80.8 million.

  • Crinetics Pharmaceuticals' Shares Outstanding (Diluted Average) rose 17.63% to $94.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.2 million, marking a year-over-year increase of 17.63%. This contributed to the annual value of $80.8 million for FY2024, which is 39.11% up from last year.
  • Crinetics Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $80.8 million in FY2024, which was up 39.11% from $58.1 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Shares Outstanding (Diluted Average) ranged from a high of $80.8 million in FY2024 and a low of $30.4 million during FY2020.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $63.6 million, with a median of $58.1 million in 2023.
  • Data for Crinetics Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 39.11% (in 2024) over the last 5 years.
  • Over the past 5 years, Crinetics Pharmaceuticals' Shares Outstanding (Diluted Average) (Yearly) stood at $30.4 million in 2020, then climbed by 26.23% to $38.4 million in 2021, then soared by 35.24% to $52.0 million in 2022, then climbed by 11.71% to $58.1 million in 2023, then soared by 39.11% to $80.8 million in 2024.